

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/520,126	10/04/2005	Koji Sode	3691-0114PUS1	9547
2292	7590 09/26/2006		EXAMINER	
BIRCH ST PO BOX 74	EWART KOLASCH	MEAH, MOHAMMAD Y		
FO BOX 747 FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1652	
			DATE MAILED: 09/26/2000	6

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application No.	No. Applicant(s)				
	10/520,126	SODE, KOJI				
Office Action Summary	Examiner	Art Unit				
	Mohammad Meah	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on						
2a) This action is <b>FINAL</b> . 2b) This	action is non-final.					
3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>1-25</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-25</u> are subject to restriction and/or election requirement.						
Application Papers		•				
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08)	3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application					
Paper No(s)/Mail Date 6)						

## Page 2

## **DETAILED ACTION**

The claims 1-25 are pending in the instant office action.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I claim(s) 1-2, 3-5 and 24-25, drawn to modified PQQGDH wherein position 192 of the amino acid sequence of SEQ ID NO: 1 is modified.

Group II claim(s) 1-2, 6-8 and 24-25, drawn to modified PQQGDH wherein positions 192 and 167 of the amino acid sequence of SEQ ID NO: 1 is modified.

Group III claim(s) 1-2, 9-11 and 24-25, drawn to modified PQQGDH wherein positions 167 and 452 of the amino acid sequence of SEQ ID NO: 1 is modified .

Group IV claim(s) 1-2, 12-14 and 24-25, drawn to modified PQQGDH wherein positions 192 and 452 of the amino acid sequence of SEQ ID NO: 1 is modified .

Group VI claim(s) 1-2, 15-17 and 24-25, drawn to modified PQQGDH wherein position 193 of the amino acid sequence of SEQ ID NO: 1 is modified.

Group VII claim(s) 1-2, 18-19 and 24-25, drawn to modified PQQGDH comprising the amino acid sequence of SEQ ID NO: 3.

Group VIII claim(s) 20-23, drawn to DNA, vector and transforment encoding modified PQQGDH of claim 1.

Application/Control Number: 10/520,126

Art Unit: 1652

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Proteins (group I- VII) and DNA (group VIII) are each unrelated and chemically distinct entity having their own special technical feature and therefore do not share same technical feature.

Groups I, II, --VII do not share their technical features because technical features of Groups I, III-IV are products, wherein each product comprises protein of unique structure having their individual technical feature.

Furthermore', the technical feature linking group I-VIII appears to be that they all relate to the modified PQQGDH of claim 1. This protein does not constitute a "special technical feature" as defined by PCT Rule 13.2, because it does not claim a feature, which defines a contribution over the prior art, as this protein is known in prior art, such as Sode (WO00/66744, Pub. Date 11/9/2000).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1652

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD Examiner, Art Unit 1652 Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261